James L Quinn

TL;DR: Overall, this manuscript provides a well-tested and standardized open field activity SOP for preclinical trials in animal models of neuromuscular diseases and provides recommendations for optimal study design when usingOpen field activity in a preclinical trial.

TL;DR: Successful improvement of dystrophy independent of hormonal, growth, or immunosuppressive effects is demonstrated, indicating VBP15 merits clinical investigation for DMD and would benefit other chronic inflammatory diseases.

TL;DR: It is found that naproxcinod treatment at 21 mg/kg resulted in significant improvement in hindlimb grip strength and a 30% decrease in inflammation in the fore- and hindlimbs of mdx mice, and major improvement in heart function, as evidenced by improved fraction shortening, ejection fraction and systolic BP.

TL;DR: Compound A, a non‐steroidal selective glucocorticoid receptor modulator, represents a potential therapeutic strategy to improve dystrophic pathology.

TL;DR: The data point to a clear role for the TLR pathway in the pathogenesis of dysferlin deficiency and suggest that TLR‐7/8 antagonists may have therapeutic value in this disease.